Cargando…

Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen

The use of pharmacogenomics to personalize drug therapy has been a long-sought goal for warfarin and tamoxifen. However, conflicting evidence has created reason for hesitation in recommending pharmacogenomics-guided care for both drugs. This review will provide a summary of the evidence to date on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wigle, Theodore J., Jansen, Laura E., Teft, Wendy A., Kim, Richard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748632/
https://www.ncbi.nlm.nih.gov/pubmed/29236081
http://dx.doi.org/10.3390/jpm7040020
_version_ 1783289436775120896
author Wigle, Theodore J.
Jansen, Laura E.
Teft, Wendy A.
Kim, Richard B.
author_facet Wigle, Theodore J.
Jansen, Laura E.
Teft, Wendy A.
Kim, Richard B.
author_sort Wigle, Theodore J.
collection PubMed
description The use of pharmacogenomics to personalize drug therapy has been a long-sought goal for warfarin and tamoxifen. However, conflicting evidence has created reason for hesitation in recommending pharmacogenomics-guided care for both drugs. This review will provide a summary of the evidence to date on the association between cytochrome P450 enzymes and the clinical end points of warfarin and tamoxifen therapy. Further, highlighting the clinical experiences that we have gained over the past ten years of running a personalized medicine program, we will offer our perspectives on the utility and the limitations of pharmacogenomics-guided care for warfarin and tamoxifen therapy.
format Online
Article
Text
id pubmed-5748632
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-57486322018-01-07 Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen Wigle, Theodore J. Jansen, Laura E. Teft, Wendy A. Kim, Richard B. J Pers Med Review The use of pharmacogenomics to personalize drug therapy has been a long-sought goal for warfarin and tamoxifen. However, conflicting evidence has created reason for hesitation in recommending pharmacogenomics-guided care for both drugs. This review will provide a summary of the evidence to date on the association between cytochrome P450 enzymes and the clinical end points of warfarin and tamoxifen therapy. Further, highlighting the clinical experiences that we have gained over the past ten years of running a personalized medicine program, we will offer our perspectives on the utility and the limitations of pharmacogenomics-guided care for warfarin and tamoxifen therapy. MDPI 2017-12-13 /pmc/articles/PMC5748632/ /pubmed/29236081 http://dx.doi.org/10.3390/jpm7040020 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wigle, Theodore J.
Jansen, Laura E.
Teft, Wendy A.
Kim, Richard B.
Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
title Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
title_full Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
title_fullStr Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
title_full_unstemmed Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
title_short Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen
title_sort pharmacogenomics guided-personalization of warfarin and tamoxifen
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748632/
https://www.ncbi.nlm.nih.gov/pubmed/29236081
http://dx.doi.org/10.3390/jpm7040020
work_keys_str_mv AT wigletheodorej pharmacogenomicsguidedpersonalizationofwarfarinandtamoxifen
AT jansenlaurae pharmacogenomicsguidedpersonalizationofwarfarinandtamoxifen
AT teftwendya pharmacogenomicsguidedpersonalizationofwarfarinandtamoxifen
AT kimrichardb pharmacogenomicsguidedpersonalizationofwarfarinandtamoxifen